First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Idorsia: the story is balanced — Clinical trial readouts for pipeline assets (selatogrel Phase 3 data for acute MI, cenerimod Phase 3 data for lupus…
1Clinical trial readouts for pipeline assets (selatogrel Phase 3 data for acute MI, cenerimod Phase 3 data for lupus, aprocitentan resistant hypertension data)
2QUVIVIQ commercial uptake metrics including prescription trends, formulary access wins, and quarterly revenue trajectory versus Street estimates
3Partnership or licensing deals that provide non-dilutive capital and validate pipeline asset value
4Regulatory submissions and approval decisions from FDA and EMA for pipeline candidates
5Cash runway updates and financing activities given negative free cash flow of $400M annually
6QUVIVIQ (daridorexant) insomnia treatment sales in US and European markets (estimated >80% of current revenue)
7Potential milestone payments and royalties from regional licensing partnerships
8Future revenue from pipeline assets upon approval (selatogrel, cenerimod, aprocitentan)
Watch on earnings: QUVIVIQ weekly prescription data (TRx and NRx trends from IQVIA or Symphony Health), Clinical trial enrollment rates and data readout timing for selatogrel, cenerimod, and aprocitentan Phase 3 programs, Quarterly cash burn rate and updated cash runway guidance.
One Sentence Summary:
Idorsia: the story is balanced — clinical trial readouts for pipeline assets (selatogrel phase 3 data for acute mi, cenerimod phase 3 data for lupus.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.